Tag Archives: OnkoSight

OPKO Health’s BioReference Laboratories Launches Best-in-Class Next-Generation Sequencing (NGS) Assay

ELMWOOD PARK, N.J., September 2, 2020 — BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), along with its specialty oncology division, GenPath, today announced the launch of OnkoSight AdvancedTM, a next-generation sequencing (NGS) assay that enables revolutionary deoxyribonucleic acid (DNA) mutational profiling of tumor samples. OnkoSight AdvancedNGS testing provides targeted gene content that is aligned with the latest […]